Journal of Hematology and Blood Disorders

Why publish with us

Built for researchers

⚡

Fast peer review

Target first decision within 21 days. Double-blind review by 2-3 field experts.

🔓

Fully open access

All articles CC BY 4.0. No paywalls. Compliant with funder mandates worldwide.

🔗

DOI & indexing

Every article receives a unique DOI. Indexed in PubMed, Google Scholar, CrossRef.

🚀

Rapid publication

Published within 7 days of acceptance. No unnecessary delays in dissemination.

🌐

Global & equitable

Readers in 170+ countries. Waiver program available for authors from developing nations.

📈

No content limits

No word limits. Multiple article formats: research, reviews, case reports, short communications.

Highlights

Research Highlights

Role of the clathrin adaptor PICALM in normal hematopoiesis and polycythemia vera pathophysiology.

Clathrin-dependent endocytosis is an essential cellular process shared by all cell types. Despite this, precisely how endocytosis is regulated in a cell-type-specific manner and how this key pathway functions physiologically or pathophysiologically remain largely unknown.

Episodic angioedema with eosinophilia (Gleich syndrome) is a multilineage cell cycling disorder.

Episodic angioedema with eosinophilia (Gleich syndrome) is a rare disorder characterized by episodes of angioedema and eosinophilia that occur at monthly intervals and resolve spontaneously without therapy.

Urine Galactomannan-creatinine Ratio for Detection of Invasive Aspergillosis in Patients with Hematologic Malignancies

Galactomannan (GM) testing of urine specimen may provide important advantages when compared to serum testing, such as noninvasive and easy sample collection. We evaluated a total of 632 serial urine samples from 71 patients with underlying hematologic malignancies.

Features associated with hematologic abnormalities and their impact in patients with systemic lupus erythematosus: Data from a multiethnic Latin American cohort

To examine hematological manifestations' correlates and their impact on damage accrual and mortality in SLE patients from the multiethnic, Latin American, GLADEL cohort.

Comparison of survival of adolescents and young adults with hematologic malignancies in Osaka, Japan

To determine to what extent it does in Japan, we investigated survival and treatment regimens in 211 Japanese AYAs (15-29 years) in the Osaka Cancer Registry diagnosed during 2001-2005 with hematological malignancies, and compared adolescents (15-19 years) with young adults (20-29 years).

Developing a risk prediction model for long-term physical and psychological functioning after hematopoietic cell transplantation

Hematopoietic cell transplantation (HCT) is associated with impaired physical and psychological functioning for some long-term survivors. A risk prediction model would help clinicians estimate their patients' physical and psychological functioning after HCT and refer to added supportive care when appropriate.

Acute myeloid leukemia in children and adolescents: identification of new molecular targets brings promise of new therapies

Recent reports of recurrent mutations in childhood acute myeloid leukemia (AML) have identified potential targets for new therapeutic strategies. Acute promyelocytic leukemia (APL) is characterized commonly by a fusion between the PML gene and the RARA gene, genes targetable by arsenic (ATO).

Patient-reported outcomes in drug development for hematology

Patient-reported outcomes (PROs) are any outcome evaluated directly by the patient himself and based on the patient's perception of a disease and its treatment(s). PROs are direct outcome measures that can be used as clinical meaningful endpoints to characterize treatment benefit. They provide unique and important information about the effect of treatment from a patient's view.

Platelet transfusion goals in oncology patients

Despite the advances in platelet component preparation and transfusion support over the years, platelet products remain a limited resource due to their short (5 day) shelf life, and therefore their optimal use in the non-bleeding thrombocytopenic patient continue to draw much attention. There have been a number of national and international guidelines for platelet transfusion therapy in patients with hematologic diseases.

Red blood cell transfusion for hematologic disorders

Randomized clinical trials (RCTs) have determined, in surgical and critically ill patients, relatively safe hemoglobin (Hb) thresholds of 7-8 g/dL to guide restrictive transfusion of red blood cells (RBCs). However, in patients with various hematologic disorders, strong evidence in support of such an approach is sparse and the optimal transfusion practice is yet to be defined.